1. TRK Inhibitors in Non-Small Cell Lung Cancer.
- Author
-
Harada G, Gongora ABL, da Costa CM, and Santini FC
- Subjects
- Antineoplastic Agents pharmacology, Biomarkers, Tumor, Carcinoma, Non-Small-Cell Lung diagnosis, Carcinoma, Non-Small-Cell Lung etiology, Carcinoma, Non-Small-Cell Lung mortality, Disease Management, Disease Susceptibility, Humans, Lung Neoplasms diagnosis, Lung Neoplasms etiology, Lung Neoplasms mortality, Molecular Diagnostic Techniques, Molecular Targeted Therapy adverse effects, Molecular Targeted Therapy methods, Neoplasm Metastasis, Neoplasm Staging, Prognosis, Protein Kinase Inhibitors pharmacology, Treatment Outcome, Antineoplastic Agents therapeutic use, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Protein Kinase Inhibitors therapeutic use, Receptor Protein-Tyrosine Kinases antagonists & inhibitors
- Abstract
Opinion Statement: Care should be taken to ensure that the diagnostic strategy for a recently diagnosed advanced non-small cell lung cancer includes NTRK fusion testing. RNA sequencing is the gold standard method of detection of NTRK fusion; however, pan-TRK immunohistochemistry could be used as a screening method with good sensitivity. Larotrectinib and entrectinib are approved therapies for TRK fusion-positive lung cancers as first or subsequent lines of therapy. TRK inhibition has demonstrated clinically meaningful, deep, and durable systemic and central nervous system responses. Larotrectinib and entrectinib have a manageable safety profile, including some TRK-related adverse events, such as dizziness and weight gain. At disease progression on first-generation TRK inhibitors, enrollment on a clinical trial should be encouraged, as new-generation TRK inhibitors are being tested.
- Published
- 2020
- Full Text
- View/download PDF